GKOS: Glaukos Corp.
About
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Key Details
Market Cap
$7.95B
P/E Ratio
-48.69
1Y Stock Return
129.45%
1Y Revenue Growth
18.70%
Dividend Yield
0.00%
Price to Book
11.9
Strategies that include GKOS
Stock's related to GKOS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VCEL | 42.97% | $2.76B | +55.60% | 0.00% |
| KN | 42.77% | $1.60B | +12.19% | 0.00% |
| CGNX | 42.68% | $6.73B | +6.19% | 0.78% |
| APAM | 42.66% | $3.25B | +26.70% | 6.08% |
| ASR | 42.51% | $7.56B | +26.22% | 0.00% |
| KFRC | 41.94% | $1.10B | -8.71% | 0.66% |
| NOVT | 41.89% | $5.95B | +15.14% | 0.00% |
| SLAB | 41.21% | $3.19B | -2.58% | 0.00% |
| GMS | 40.62% | $3.90B | +50.71% | 0.00% |
| LFUS | 40.19% | $5.90B | +1.26% | 1.12% |
| ICUI | 39.90% | $4.15B | +104.38% | 0.00% |
| FUN | 39.89% | $4.60B | -16.51% | 0.00% |
| CDXS | 39.52% | $345.86M | +121.35% | 0.00% |
| TPIC | 39.51% | $96.08M | -13.30% | 0.00% |
| CADE | 39.35% | $6.82B | +53.20% | 2.64% |
| ALKT | 39.24% | $3.80B | +65.83% | 0.00% |
| CCS | 39.23% | $2.69B | +20.00% | 1.19% |
| BASE | 38.95% | $1.04B | +8.03% | 0.00% |
| QTWO | 38.80% | $6.02B | +186.81% | 0.00% |
| POWI | 38.79% | $3.44B | -21.30% | 1.33% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BNED | -<0.01% | $277.22M | -91.94% | 0.00% |
| CORZ | 0.01% | $4.60B | +3,201.26% | 0.00% |
| CVS | 0.01% | $70.18B | -18.08% | 4.72% |
| WCN | -0.04% | $48.39B | +42.47% | 0.62% |
| SPOK | -0.07% | $323.34M | -6.07% | 7.89% |
| V | -0.11% | $595.29B | +23.64% | 0.69% |
| MNST | 0.16% | $52.25B | -1.95% | 0.00% |
| HIG | -0.19% | $33.87B | +51.09% | 1.60% |
| T | -0.19% | $163.09B | +40.40% | 4.87% |
| AIXI | -0.20% | $43.94M | -72.60% | 0.00% |
| APLS | 0.22% | $3.61B | -41.27% | 0.00% |
| EGHT | 0.23% | $351.48M | -7.88% | 0.00% |
| OKLO | 0.29% | $2.66B | +111.04% | 0.00% |
| LLY | 0.30% | $692.74B | +23.14% | 0.71% |
| VKTX | 0.39% | $5.74B | +353.83% | 0.00% |
| SFM | 0.39% | $14.34B | +254.87% | 0.00% |
| KNSL | 0.43% | $10.93B | +29.38% | 0.13% |
| GSHD | -0.43% | $2.86B | +64.45% | 0.00% |
| OLLI | 0.45% | $5.48B | +15.97% | 0.00% |
| GIFI | 0.45% | $114.47M | +68.27% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AEE | -29.53% | $24.59B | +20.10% | 2.87% |
| EXC | -27.42% | $39.29B | +0.57% | 3.88% |
| GIS | -21.00% | $34.85B | -2.91% | 3.78% |
| AJG | -19.27% | $64.17B | +17.51% | 0.80% |
| PG | -19.09% | $402.15B | +14.14% | 2.33% |
| WEC | -17.30% | $31.33B | +22.40% | 3.38% |
| PEP | -16.70% | $215.02B | -6.60% | 3.35% |
| MDLZ | -16.57% | $85.41B | -10.00% | 2.73% |
| CLX | -16.24% | $20.81B | +20.66% | 2.88% |
| CAH | -16.23% | $28.64B | +12.14% | 1.70% |
| NOC | -16.21% | $71.54B | +4.23% | 1.60% |
| MMC | -15.06% | $108.41B | +10.89% | 1.37% |
| CBOE | -14.90% | $21.46B | +15.84% | 1.11% |
| ETR | -14.78% | $32.14B | +49.00% | 3.05% |
| ED | -14.38% | $33.59B | +7.16% | 3.43% |
| CME | -14.27% | $82.76B | +9.21% | 1.98% |
| PGR | -13.68% | $149.10B | +57.29% | 0.45% |
| HUSA | -13.60% | $16.69M | -11.56% | 0.00% |
| CHD | -13.32% | $27.18B | +19.50% | 1.03% |
| AON | -12.88% | $82.00B | +16.33% | 0.70% |
ETF's related to GKOS
News
Finnhub
Investor Presentation November 2024 Disclaimer All statements...
Finnhub
ALISO VIEJO - Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today...
Yahoo
Glaukos Corporation ( NYSE:GKOS ) just released its latest third-quarter results and things are looking bullish...
SeekingAlpha
The Fund returned 6.41%, reflecting performance at the NAV of Class I shares with all distributions reinvested for the quarter ended September 30, 2024.
Yahoo
Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $145 from $135 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q3 sales beating consensus, driven by iDose and OUS MIGS. Management raised sales guidance by $5M at the midpoint, or the magnitude of the beat. Wells sees good momentum for iDose into Q4 and 2025. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRa
Yahoo
Glaukos ( NYSE:GKOS ) Third Quarter 2024 Results Key Financial Results Revenue: US$96.7m (up 24% from 3Q 2023). Net...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.